Biogen vs Gilead Sciences vs Incyte and 2 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Biogen 2.736, Gilead Sciences 7.803, Incyte 1.674, Vertex Pharmaceuticals 3.334, Henry Schein 3.458.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Biogen, Gilead Sciences, Incyte, Vertex Pharmaceuticals, Henry Schein.| Metric | Biogen | Gilead Sciences | Incyte | Vertex Pharmaceuticals | Henry Schein |
|---|---|---|---|---|---|
| Market Cap | $32.66B | $183.62B | $25.97B | $138.72B | $10.07B |
| Revenue | $2.74B | $7.80B | $1.67B | $3.33B | $3.46B |
| Cost of Revenue | $1.18B | $1.58B | $105.00M | $489.00M | $2.36B |
| Gross Profit | $1.56B | $6.22B | $1.57B | $2.85B | $1.10B |
| Operating Income | $318.00M | $-10.39B | $698.00M | $1.25B | $200.00M |
| Net Income | $98.00M | $-10.50B | $586.00M | $1.10B | $94.00M |
| R&D Expense | $496.00M | $1.76B | $517.00M | $994.00M | $0 |
| Earnings Per Share | $0.66 | -$8.45 | $2.81 | $4.31 | $0.82 |
| Gross Margin | 56.9% | 79.8% | 93.7% | 85.3% | 31.8% |
| Operating Margin | 11.6% | -133.2% | 41.7% | 37.4% | 5.8% |
| Net Profit Margin | 3.6% | -134.5% | 35.0% | 33.0% | 2.7% |
| Free Cash Flow | $490.00M | $3.69B | $495.00M | $1.01B | $196.00M |
| Cumulative Free Cash Flow | $47.88B | $155.83B | $3.86B | $17.24B | $9.89B |
| Operating Cash Flow | $449.00M | $3.57B | $508.00M | $1.13B | $242.00M |
| Cash & Equivalents | $1.28B | $3.18B | $3.98B | $6.14B | $157.00M |